The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.
Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.
The RTP life sciences development company will apply the funding to the clinical development of Resusix®, its proprietary dehydrated pathogen-inactivated human plasma that holds promise as a substitute for fresh frozen plasma (FFP) in certain applications.
ShareThis Email PDF Print
Entegrion logo
We view this as a strong vote of confidence from the world’s leading defense organization. This contract award positions the company as a strategic player in the mainstream of blood plasma research and development.
Research Triangle Park, NC (PRWEB) October 04, 2011
Royal Philips Electronics (NYSE:PHG) is adding a robotic system to its treatment options for clogged heart arteries in a new pact with Natick, Mass.-based Corindus Inc.
For its 9th birthday, the biotech Entegrion is giving itself a present: a product on the market.
The Research Triangle Park, N.C.-based company struck a licensing deal with a Boston-based medical device company to manufacture and market Entegrion’s Stasilon bandage: a proprietary weave of glass and bamboo fibers that promotes clotting. CTO Joseph DaCorta wouldn’t name the company Beantown partner, but DaCorta did say that the business expects to make an announcement this week.
